Oncology

Ibrutinub plus obinutuzumab is the first FDA-approved non-chemotherapy combination regimen for chronic lymphocytic lymphoma and small lymphocytic lymphoma.

How to treat hepatocellular carcinoma is heavily influenced by the burden of disease at diagnosis.

Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia.

Officials with the FDA approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.

Top news of the day across the health care landscape.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, gives an overview of the exciting therapeutic developments in the B-cell lymphoma space.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Patients with low-risk prostate cancer that harbors certain genetic alterations may have a higher risk of disease progression.

Top news of the day across the health care landscape.

A newly-developed biomedical device may help prevent chemotherapy from spreading away from the targeted tumor.

Top news of the day across the health care landscape.

Study suggests a new therapy could stop tumor growth by affecting myeloid cell behavior.

Advancements in cancer therapy have improved survival time for patients with non-small cell lung cancer (NSCLC), according to a new study published in the Journal of Thoracic Oncology.

Advancements in targeted therapies have helped significantly improve survival in late-stage anaplastic lymphoma kinase positive non-small cell lung cancer.

Study finds at least a 1.5-fold difference between states with lowest and highest proportions of cancers related to obesity.

Researchers aimed to better understand the different ways that breast cancer avoids immune system detection.

Top news of the week from Specialty Pharmacy Times.

Durvalumab plus tremelimumab did not meet the primary endpoint of the phase 3 MYSTIC trial evaluating improvement in overall survival and progression-free survival compared with chemotherapy.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the increasing cost burden of cancer therapies and future strategies for mitigating costs.

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer.

Officials with the FDA have approved romiplostim (NPLATE, Amgen) for the treatment of immune thrombocytopenia (ITP) in pediatric patients aged 1 year and older.

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.

Hot flashes are a huge problem across the general population, but even more so in breast cancer survivors.

Immunotherapy checkpoint inhibitors have changed the landscape of oncology treatment, however, they can come with a risk of adverse effects and, in rare cases, cause serious medical problems.

Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.

An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.